JP Morgan Maintains Neutral on Teladoc Health, Raises Price Target to $10
JP Morgan analyst Lisa Gill maintains Teladoc Health (NYSE:TDOC) with a Neutral and raises the price target from $8 to $10.
Share
Why It Matters
A big bank analyst thinks Teladoc is worth more money now. But they still say the stock is just okay, not great or bad.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.